Rewind Therapeutics

Rewind Therapeutics is developing novel re-myelinating therapies for patients suffering from Multiple Sclerosis and other myelin-related diseases. In close collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3), Axxam S.p.A. and a world-class academic network, Rewind Therapeutics aspires to advance innovative first-in-class therapies to the clinic. Rewind Therapeutics is based in Leuven, Belgium.

Team Members
more about
Cheryl Zimberlin
more about
Bauke Anninga
Latest News Entry
Rewind Therapeutics appoints leading neuroscience drug developer Ian J. Reynolds as Chief Executive Officer

Rewind Therapeutics (“Rewind”), a private Belgian biotech company developing innovative first-in-class therapies for myelin-related diseases announces the appointment of Ian J. Reynolds as its Chief Executive Officer (CEO)

Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies
all portfolio news